Epratuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Epratuzumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD22
Clinical data
Trade names LymphoCide
Legal status Investigational
Identifiers
CAS number 205923-57-5 N
ATC code None
PubChem SID47206001
DrugBank DB04958
UNII 3062P60MH9 YesY
KEGG D04036 YesY
Chemical data
Formula ?
 N (what is this?)  (verify)

Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).[1][2] The manufacturers in August 2009 announced success in early trials against SLE,[3] and the drug is in Phase III clinical trials as of February 2014.[4]

Mechanism of action[edit]

Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells.

References[edit]

  1. ^ Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties Clinical Cancer Research Vol. 9, September 1, 2003 free full text
  2. ^ Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab Clinical Cancer Research Vol. 11, July 15, 2005 free full text
  3. ^ Reuters: UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study in Systemic Lupus Erythematosus (SLE)
  4. ^ H. Spreitzer (3 February 2014). "Neue Wirkstoffe – Epratuzumab". Österreichische Apothekerzeitung (in German) (3/2014): 28.